Directed removal of FXN GAA expansion was then tested in CD34+ HSPCs from FRDA patients, and we demonstrated gene editing of 12.1–55.9% with a mean of 29.66%, across multiple patients, and with excision of >1,000 repeats. The gene discussed is CD34; the disease is Friedreich ataxia.